尽管出现了多替拉韦耐药性变体，但病毒血症水平较低。 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

尽管出现了多替拉韦耐药性变体，但病毒血症水平较低。 - Suppr | 超能文献

Low-level viraemia despite emergence of dolutegravir-resistant variants.

作者信息

Botha Johannes C, Steegen Kim, Edoo Mariam, Nel Jeremy, van Zyl Gert U

机构信息

Department of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Department of Molecular Medicine and Haematology, Faculty of Health Sciences, National Health Laboratory Service, Johannesburg, South Africa.

出版信息

South Afr J HIV Med. 2022 Sep 30;23(1):1398. doi: 10.4102/sajhivmed.v23i1.1398. eCollection 2022.

DOI:10.4102/sajhivmed.v23i1.1398

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9575371/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934c/9575371/d002c6d7fe95/HIVMED-23-1398-g002.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934c/9575371/e225696a2bbb/HIVMED-23-1398-g001.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934c/9575371/d002c6d7fe95/HIVMED-23-1398-g002.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934c/9575371/e225696a2bbb/HIVMED-23-1398-g001.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/934c/9575371/d002c6d7fe95/HIVMED-23-1398-g002.jpg

相似文献

1

Low-level viraemia despite emergence of dolutegravir-resistant variants.尽管出现了多替拉韦耐药性变体，但病毒血症水平较低。

South Afr J HIV Med. 2022 Sep 30;23(1):1398. doi: 10.4102/sajhivmed.v23i1.1398. eCollection 2022.

2

Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.单用度鲁特韦或拉替拉韦均不能持久抑制人源化小鼠的 HIV 病毒血症。

J Antimicrob Chemother. 2017 Sep 1;72(9):2570-2573. doi: 10.1093/jac/dkx195.

3

Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.整合酶耐药性的出现与拉米夫定联合多替拉韦治疗既往 HIV-1 抑制。

J Antimicrob Chemother. 2022 May 29;77(6):1738-1740. doi: 10.1093/jac/dkac082.

4

Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.在接受比克替拉韦、恩曲他滨和丙酚替诺福韦二吡呋酯固定剂量复方制剂与多替拉韦为基础的方案维持治疗的 HIV 感染者中，低水平病毒血症和病毒学失败情况。

Int J Antimicrob Agents. 2022 Sep;60(3):106631. doi: 10.1016/j.ijantimicag.2022.106631. Epub 2022 Jul 1.

5

Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.多替拉韦单药治疗 HIV 感染者的长期随访。

J Antimicrob Chemother. 2020 Mar 1;75(3):675-680. doi: 10.1093/jac/dkz478.

6

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.拉替拉韦治疗失败的患者中出现较高频率的多替拉韦耐药。

J Antimicrob Chemother. 2015 Mar;70(3):926-9. doi: 10.1093/jac/dku439. Epub 2014 Nov 10.

7

Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5 years and older.5 岁及以上感染 HIV-1 的儿科和青少年患者中，多替拉韦在各年龄组间的疗效和安全性相似。

HIV Med. 2019 Sep;20(8):561-566. doi: 10.1111/hiv.12752. Epub 2019 May 29.

8

Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study.基于多替拉韦的联合抗逆转录病毒疗法在围产期感染HIV-1的青少年中的疗效和耐受性：一项法国多中心回顾性研究。

J Antimicrob Chemother. 2017 Mar 1;72(3):837-843. doi: 10.1093/jac/dkw464.

9

HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia.即使对于低水平病毒血症患者，HIV-1整合酶基因分型在整合酶耐药突变的常规临床检测中也是可靠且可重复的。

J Antimicrob Chemother. 2015;70(6):1865-73. doi: 10.1093/jac/dkv029. Epub 2015 Feb 23.

10

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.两种药物联合治疗方案，包括多替拉韦加利匹韦林或拉米夫定，用于初治、病毒学抑制的 HIV-1 患者：来自文献的最新疗效和安全性证据。

J Glob Antimicrob Resist. 2020 Mar;20:228-237. doi: 10.1016/j.jgar.2019.08.010. Epub 2019 Aug 22.

引用本文的文献

1

High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana.在博茨瓦纳弗朗西斯敦接受基于多替拉韦的抗逆转录病毒治疗的艾滋病毒感染者中，逆转录酶抑制剂相关耐药突变的高流行率。

J Antimicrob Chemother. 2025 Mar 3;80(3):767-776. doi: 10.1093/jac/dkae472.

2

Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir.寡核苷酸连接分析（OLA）探针用于检测 HIV-1 对多替拉韦耐药的开发和优化。

Viruses. 2024 Jul 19;16(7):1162. doi: 10.3390/v16071162.

3

本文引用的文献

1

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.多替拉韦或达芦那韦联合拉米夫定加齐多夫定或替诺福韦用于治疗 HIV 感染的二线治疗的疗效和安全性（NADIA）：一项前瞻性、多中心、开放标签、析因、随机、非劣效性试验的第 96 周结果。

Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20.

2

HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus.抗逆转录病毒治疗无法抑制的 HIV-1 病毒血症可能来源于产生感染性病毒的大 T 细胞克隆。

J Clin Invest. 2020 Nov 2;130(11):5847-5857. doi: 10.1172/JCI138099.

3

Geospatial and temporal mapping of detectable HIV-1 viral loads amid dolutegravir rollout in KwaZulu-Natal, South Africa.

南非夸祖鲁-纳塔尔省多替拉韦推广期间可检测到的HIV-1病毒载量的地理空间和时间映射。

PLOS Glob Public Health. 2024 May 28;4(5):e0003224. doi: 10.1371/journal.pgph.0003224. eCollection 2024.

4

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.初治人类免疫缺陷病毒 1 型整合酶抑制剂人群中出现的治疗中出现的多替拉韦耐药突变：快速范围界定综述。

Viruses. 2023 Sep 15;15(9):1932. doi: 10.3390/v15091932.

Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases.一线或二线抗逆转录病毒治疗初治患者中对多替拉韦的紧急耐药性：已发表病例综述

Open Forum Infect Dis. 2020 Jun 2;7(6):ofaa202. doi: 10.1093/ofid/ofaa202. eCollection 2020 Jun.

4

A systematic review of the genetic mechanisms of dolutegravir resistance.多替拉韦耐药的遗传机制的系统评价。

J Antimicrob Chemother. 2019 Nov 1;74(11):3135-3149. doi: 10.1093/jac/dkz256.

5

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.多替拉韦与利托那韦增强洛匹那韦联合双核苷逆转录酶抑制剂治疗在一线治疗失败的 HIV-1 感染成人中的疗效（DAWNING）：一项开放标签、非劣效性、3b 期临床试验。

Lancet Infect Dis. 2019 Mar;19(3):253-264. doi: 10.1016/S1473-3099(19)30036-2. Epub 2019 Feb 4.

6

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible.基于多替拉韦的一线治疗方案用于HIV三联疗法时出现病毒学失败：罕见但有可能。

Open Forum Infect Dis. 2018 Dec 10;6(1):ofy332. doi: 10.1093/ofid/ofy332. eCollection 2019 Jan.

7

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.多替拉韦钠单药维持治疗与拉米夫定联合治疗：DOLAM 随机临床试验的 24 周计划分析。

J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971. doi: 10.1093/jac/dky093.

8

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.R263K多替拉韦耐药相关替代突变会逐渐降低HIV-1整合。

mBio. 2017 Apr 4;8(2):e00157-17. doi: 10.1128/mBio.00157-17.

9

Emergent drug resistance with integrase strand transfer inhibitor-based regimens.基于整合酶链转移抑制剂方案的紧急耐药性。

AIDS. 2017 Jun 19;31(10):1425-1434. doi: 10.1097/QAD.0000000000001494.

10

Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA.用于测量总细胞相关HIV-1 DNA和RNA的新型检测方法。

J Clin Microbiol. 2016 Apr;54(4):902-11. doi: 10.1128/JCM.02904-15. Epub 2016 Jan 13.